Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
190
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report

Yubo PiDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8971-5517View further author information
ORCID Icon,
Jingshi WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaView further author information
&
Zhao WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 3751-3756 | Published online: 13 Jul 2022

References

  • Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93–105. doi:10.1002/rmv.638
  • El-Mallawany NK, Curry CV, Allen CE. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. Br J Haematol. 2022;196(1):31–44. doi:10.1111/bjh.17638
  • Lai W, Wang Y, Wang J, Wu L, Jin Z, Wang Z. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-A life-threatening disease: analysis of 133 cases from a single center. Hematology. 2018;23(10):810–816. doi:10.1080/10245332.2018.1491093
  • Zeng X, Wei N, Wang Y, et al. [Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis]. Zhonghua Xue Ye Xue Za Zhi. 2015;36(6):507–510. Chinese. doi:10.3760/cma.j.issn.0253-2727.2015.06.013
  • Henter JI, Samuelsson-Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373. doi:10.1182/blood-2002-01-0172
  • Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi:10.1002/pbc.21039
  • Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9(1):84. doi:10.1186/s13045-016-0317-7
  • Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186–2192. doi:10.1182/blood-2015-05-644914
  • Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135(11):826–833. doi:10.1182/blood.2019003886
  • Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221(5):278–285. doi:10.1055/s-0029-1237386
  • Gooptu M, Kim HT, Jacobsen ED, et al. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2022. doi:10.1182/bloodadvances.2022007012
  • Machowicz R, Suarez F, Wiktor-Jedrzejczak W, et al. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. Bone Marrow Transplant. 2022;57(5):817–823. doi:10.1038/s41409-022-01634-5
  • Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8(8):1597. doi:10.3389/fimmu.2017.01597
  • Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24(1):47–53. doi:10.1097/PPO.0000000000000303
  • Kuzume A, Chi S, Yamauchi N, Minami Y. Immune-checkpoint blockade therapy in lymphoma. Int J Mol Sci. 2020;21:15. doi:10.3390/ijms21155456
  • Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129(18):2471–2478. doi:10.1182/blood-2016-11-749556
  • Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130(2):221–228. doi:10.1182/blood-2017-01-761346
  • Thummalapalli R, Heumann T, Stein J, et al. Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma. Case Rep Oncol. 2020;13(2):508–514. doi:10.1159/000507281

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.